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Results
The pooled study population had a median follow-up time of 17.3 years (range 0-35.0) since cohort entry. In total, 5,144 (32.5%) patients received doxorubicin while 2,243 (14.7%) patients received daunorubicin. Based on 271 HF cases, the cumulative incidence of HF at age 40 for the entire pooled cohort was 3.2% (95% Confidence Interval [CI] 2.8-3.7%). The average equivalence ratio of daunorubicin to doxorubicin HRs in increments of 100 mg/m 2 was 0.45 (95% CI 0.23-0.73). A similar equivalence ratio was obtained when the association between each agent and HF was modeled using a linear dose-response model, 0.49 (95% CI 0.28-0.70).
Conclusion
Compared with doxorubicin, daunorubicin appeared substantially less cardiotoxic among childhood cancer survivors than most current guidelines suggest. This may have implications for follow-up guidelines. Assuming similar cancer therapeutic efficacy, the feasibility of substituting doxorubicin with less cardiotoxic daunorubicin in childhood cancer treatment protocols should be investigated further.
